Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.
(317.15 KB)
. 
Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.
(475.29 KB)
. 
A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.
(336.66 KB)
. 
Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48.
(309.47 KB)
. 
The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.
(233.18 KB)
. 
Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10169):330-339.
(10.3 MB)
. . 
Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.
(529.81 KB)
. . 
Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.
(447.63 KB)
. 
Pregnancy hypertension diagnosis and care in COVID‐19 era and beyond. Ultrasound in Obstetrics & Gynecology. 2020;56(1):7 - 10.
(263.08 KB)
. 
Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open. 2019;9(2):e024042.
(2.94 MB)
. 
Pre-eclampsia. Lancet. 2016;387(10022):999-1011.
(128.83 KB)
. 
Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1
. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.
(292.91 KB)
. 
Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.
(85.31 KB)
. 
PRE-EMPT Selected scientific abstracts, 2011-2019. 2019;:1-81.
(21.32 MB)
. 
Potential for task-sharing to Lady Health Workers for identification and emergency management of pre-eclampsia at community level in Pakistan. Reprod Health. 2016;13(Suppl 2):107.
(286.51 KB)
. 
A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238.
(925.17 KB)
. 
Pregnancy and Long-Term Maternal Cardiovascular Health: Progress Through Harmonization of Research Cohorts and Biobanks. Hypertension. 2016;67(2):251-60.
(854.88 KB)
. 
Pre-eclampsia. Lancet. 2010;376(9741):631-44.
(809.94 KB)
. 
Periconception mHealth platform for prevention of placental-related outcomes and non-communicable diseases. Placenta. 2017;60:115-118.
(428.43 KB)
. 
Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC Med. 2017;15(1):68.
(932.74 KB)
. 
Policy review on the management of pre-eclampsia and eclampsia by community health workers in Mozambique. Human Resources for Health [Internet]. 2019;17(1). https://human-resources-health.biomedcentral.com/articles/10.1186/s12960-019-0353-9http://link.springer.com/content/pdf/10.1186/s12960-019-0353-9.pdf
(687.16 KB)
. 
The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network’s first protocol: deep phenotyping in three sub-Saharan African countries. Reproductive Health. 2020;17(S1).
(1.89 MB)
. 
The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) database: open-access data collection in maternal and newborn health. Reproductive Health. 2020;17(S1).
(1.21 MB)
. 
PRECISE pregnancy cohort: challenges and strategies in setting up a biorepository in sub-Saharan Africa. Reproductive Health. 2020;17(S1).
(633.9 KB)
. 
Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.
(501.41 KB)
. 
Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.
(986.49 KB)
. 
Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia. Sci Rep. 2018;8(1):6342.
(3.16 MB)
. 
Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.
(389.82 KB)
. 
Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.
(322.96 KB)
. 
Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.
(486.35 KB)
. 
PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.
(183.96 KB)
. 
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.
(201.46 KB)
. 